Steve Potts has been a vocal supporter of the urgent need to modify the Inflationary Reduction Act to avoid further ongoing harm to small molecule drug development, and has spoken on this topic in many audiences, including testifying in the US Congress. 

He has worked in oncology since 1999 and has experience in a wide range of areas across drug development and diagnostics, including medical affairs, clinical trials, product development, sales, marketing, and general management. He founded the multi-armed viral immunotherapy company, OncoMyx, in 2018 and raised  $75M total of venture funding. Previously, he was Vice President of Medical Affairs at Ignyta, which was acquired by Roche/Genentech in 2017, and he led the global operation of the testing of over 20,000 patients in an oncology basket trial for entrectinib in 15 countries. The ROS1 & TRK kinase inhibitor, now launched by Roche (www.rozlytrek.com), was the first in the industry to receive simultaneous breakthrough designation equivalents in USA, Europe, and Japan, and also one of the first to run a global concurrent registrational adult and pediatric trial. Prior to this he founded several companies with high return exits to investors in oncology pathology diagnostics and pharma services. He also built the first bioinformatics department at Quest Diagnostics, supporting one of the USA's largest next generation sequencing clinical laboratories. He earned his PhD in Bioengineering from UC Davis, an MBA from UC Davis, and a BS in Physics from Wheaton College, Illinois. He lives in Peoria, Arizona.

Justin has been involved in patient recruitment and engagement for the entirety of his 10+ year career in research. His experience spans multiple sectors, including in-hospital settings, CROs/SMOs, and pharmaceutical companies. His core focus is developing innovative solutions to address challenging clinical trial enrollment criteria and timelines. He is particularly passionate about the intersection of engagement strategies, artificial intelligence, digital media channels, and patient advocacy group relationships. Through these efforts, Justin consistently aims to achieve repeatable and quantifiable results. As Director of Global Patient Recruitment & Engagement at Alexion, he is building global processes to incorporate patient voices into trial design, creating targeted marketing and awareness campaigns, and streamlining internal processes. His ultimate goal is to accelerate research accessibility for those who need it most, while simultaneously reducing barriers, costs, and resource burdens associated with external engagement activities. His background in medicinal chemistry, web development, graphic design and desktop publishing, and digital campaign strategy/development/execution has afforded a rich and unique career path in clinical research.

Dr Timothy London is the Director of Molecular Biology & Cell Engineering at RoukenBio, where he leads the development of cutting-edge cell line engineering platforms and novel solutions. With a PhD in Molecular Biology from the University of Cambridge, Dr London has over a decade of experience in biopharmaceutical research, including MedImmune where he was involved in antibody discovery and optimization campaigns, and TC BioPharm, where he played a pivotal role in developing early-stage CAR-T programs. At RoukenBio, he has spearheaded innovations in inducible expression systems and expanded the company’s services to include custom cell line engineering. Dr London is a co-inventor on multiple patents in CAR-T therapies and cell line development. Passionate about advancing therapeutics that improve patient outcomes, he thrives on tackling the unique challenges presented by diverse client projects. Join Dr London at IO360 to learn how RoukenBio’s cutting-edge solutions like IndEx-2 can accelerate your therapeutic development.

TBA

Jennifer L. Frahm, PhD, is the Director of Global Field Applications at Standard BioTools. In this role, she leads a global team to enhance technical competencies and customer experience through innovative training programs. Dr. Frahm holds a PhD in Chemistry from North Carolina State University, where she developed methods for ovarian cancer biomarker quantification using high-resolution mass spectrometry. She also completed a postdoctoral fellowship at the University of North Carolina, Chapel Hill, studying post-translational regulation of lipid metabolism in diabetes and obesity. With over 15 years of experience in customer support, including 10 years as a Field Application Scientist in the Americas and Europe, Dr. Frahm identifies market trends and customer needs to help shape product development and improve customer satisfaction.

Jing L. Marantz, M.D., Ph.D. has over 25 years of experience in the biopharmaceutical industry spanning R&D, business development, and medical affairs in multiple specialties and rare diseases. She is currently Chief Medical Officer of Scholar Rock. Dr Marantz was previously Chief Business Officer of Krystal Biotech, after serving on its board for a year. Prior to Krystal, she was Senior Vice President of Medical Affairs of Acceleron Pharma Inc. until its acquisition by Merck & Co., Inc. Dr Marantz has held leadership positions at Alnylam, Alexion, Biogen, ARIAD, and Millennium Pharmaceuticals across development, medical affairs, and business development. Earlier in her career, she was a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. Marantz is a member of the Board of Directors for Arcturus Therapeutics, Inc. She received her medical training from Tongji Medical College, a Ph.D. in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California at Berkeley.

Dr. Jason Sager is a Cornell Medical School trained, distinguished physician-scientist with 12 years of clinical experience as a pediatric oncologist (Johns Hopkins with mentor Bert Vogelstein, NCI, and Dana Farber), and 20 years of translational clinical early drug development experience in oncology at Genentech, Novartis, Sanofi, and Ikena Oncology. He is now Chief Medical Officer of Accent Therapeutics where he leads the clinical development of Accent’s pioneering small molecule precision cancer therapies to target critical intracellular dependencies that span multiple types of cancer. He is excited to be advancing Accent’s two leading programs targeting DHX9 (ATX-559) and KIF18A (ATX-295) in the clinic. In 2014, Dr Sager also founded Sagely Health, a Health IT company, that guides cancer patients to achieve their best possible outcome, by identifying and accessing science-based innovative therapeutics and diagnostics that otherwise would likely be overlooked. On the way to constructing a web-based platform that aims to one day serve millions of patients, Dr Sager and his team have already made a significant impact by assisting more than a hundred adults and children through their personalized consultation service. Dr Sager’s experience and endeavors reflect his unwavering passion for bettering the lives of cancer patients. He is dedicated to raising, maintaining, and focusing energy into improving all aspects of the cancer system, aiming to accelerate breakthroughs while delivering high-quality, compassionate care. Outside of his professional efforts, Dr Sager enjoys spending family time hiking with his wife and two daughters, as well as cycling near his home in Newton, MA.

Dr Peter Schmidt, PhD is a neuroscientist with a wealth of experience in biomedical research. He's been an inventor, principal investigator, and mathematician with experience in neurology, psychiatry, and immunology. Before joining Rho, he was the Vice Dean at East Carolina University’s Brody School of Medicine, where he oversaw research and clinical care. During his time at the Parkinson’s Foundation, Dr Schmidt designed and led the largest clinical study of Parkinson’s disease, enrolling 12,000 patients across 30 academic medical centers in five countries. He has served in advisory and board roles for national and international organizations in clinical care, research, and patient advocacy including the National Quality Forum, the Cystic Fibrosis Foundation, and the Huntington’s Study Group. He holds two patents and has authored many peer-reviewed journal articles.

Robert "Bob" Getts, PhD serves as Chief Platform Technologies Officer and is a Co-Founder of Code Bio. Dr Getts leads all of the company’s discovery, platform development and novel application activities. He also serves as a Scientific Advisor for AllerGenis LLC; as a member of the Rowan University Biomedical Engineering Industrial and Medical Advisory Board; as an Associate Clinical Preceptor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy; and as a graduate program advisor at Thomas Jefferson University and The University of Maryland.

Dr Getts possesses more than 25 years of experience using nanotechnologies as tools to develop life science reagents, kits, and diagnostic assays. Most recently he served as the Chief Scientific Officer and acting CEO at Genisphere, LLC. where he led the development of 3DNA as a novel non-viral targeted delivery platform for the delivery of multiple types of therapeutic cargo including small drugs, siRNA, biologics, and whole genes.

Dr Getts has a PhD in Biochemistry from Lehigh University, has over 40 peer-review publications, abstracts, and presentations, and is listed as an inventor on more than 20 issued patents and over 35 US and international patent applications.

Lorna Allen is the Senior Involvement Manager at the Cystic Fibrosis Trust, the only UK charity representing people living with CF and their families.  Lorna leads the Community Involvement workstream ensuring the work of the Trust, scientific researchers, industry partners and external stakeholders are informed and influenced by the experience and expertise of people and families living with the condition.  Community insights accurately reflect the rapid evolution of change in CF of recent years, providing clarity to strategic priority setting, objectives and investment decisions.  Lorna is also mother to her 26 year old daughter with CF.